Advaxis, Inc. (ADXS) Analysts See $-0.14 EPS

Advaxis, Inc. (NASDAQ:ADXS) LogoInvestors sentiment decreased to 0.6 in Q2 2018. Its down 0.54, from 1.14 in 2018Q1. It turned negative, as 25 investors sold Advaxis, Inc. shares while 15 reduced holdings. 12 funds opened positions while 12 raised stakes. 11.71 million shares or 31.07% less from 16.99 million shares in 2018Q1 were reported.
Citadel Advsr Limited Liability Co reported 24,871 shares stake. Rbf Cap Ltd Com stated it has 0.01% in Advaxis, Inc. (NASDAQ:ADXS). Franklin Street Advsr Inc Nc reported 0.03% stake. National Bank & Trust Of Montreal Can holds 0% or 2,259 shares in its portfolio. California Public Employees Retirement Sys reported 47,900 shares. Quantitative Invest Mngmt Limited Liability Com has 0% invested in Advaxis, Inc. (NASDAQ:ADXS) for 26,700 shares. The California-based Capital Fin Advisers has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Morgan Stanley stated it has 228,373 shares or 0% of all its holdings. Dafna Capital Mngmt Lc stated it has 0.47% in Advaxis, Inc. (NASDAQ:ADXS). Price T Rowe Assoc Md reported 57,000 shares or 0% of all its holdings. Tower Rech Llc (Trc) invested in 0% or 1,625 shares. Deutsche Commercial Bank Ag, a Germany-based fund reported 30,661 shares. Pub Employees Retirement Association Of Colorado invested 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Geode Ltd Liability reported 0% in Advaxis, Inc. (NASDAQ:ADXS). Edge Wealth Mngmt Limited Co invested 0% in Advaxis, Inc. (NASDAQ:ADXS).

Analysts expect Advaxis, Inc. (NASDAQ:ADXS) to report $-0.14 EPS on December, 19.They anticipate $0.43 EPS change or 75.44 % from last quarter’s $-0.57 EPS. After having $-0.27 EPS previously, Advaxis, Inc.’s analysts see -48.15 % EPS growth. The stock decreased 5.01% or $0.0208 during the last trading session, reaching $0.3941. About 385,469 shares traded. Advaxis, Inc. (NASDAQ:ADXS) has declined 85.08% since December 7, 2017 and is downtrending. It has underperformed by 100.70% the S&P500.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

Among 2 analysts covering Advaxis (NASDAQ:ADXS), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Advaxis had 2 analyst reports since June 8, 2018 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Friday, June 8 with “Buy”. The firm has “Hold” rating by Jefferies given on Wednesday, June 13.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $27.39 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

More notable recent Advaxis, Inc. (NASDAQ:ADXS) news were published by: Seekingalpha.com which released: “Your Cancer Highlight: Advaxis Resurrects A ‘Dead’ Bone Cancer Program – Seeking Alpha” on September 04, 2018, also Seekingalpha.com with their article: “Advaxis licenses ADXS-HER2 to OS Therapies for evaluation in the treatment of osteosarcoma – Seeking Alpha” published on September 04, 2018, Seekingalpha.com published: “Advaxis Makes A Bold Strategic Move, Was There A Major Logical Reason Behind It? – Seeking Alpha” on June 11, 2018. More interesting news about Advaxis, Inc. (NASDAQ:ADXS) were released by: Seekingalpha.com and their article: “Investors returning to tiny biotechs – Seeking Alpha” published on November 16, 2018 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Advaxis (NASDAQ:ADXS) Posts Narrower Loss, Endocyte (NASDAQ:ECYT) Announces $175M Offering, Leadership Transition At Insulet (NASDAQ:PODD) – Benzinga” with publication date: September 11, 2018.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.